Akershus University Hospital
Lørenskog, Nordbyhagen, 1478, Norway
Completed
NCT Number: NCT04573491
Implementation of Pharmacogenetic Testing in Hospital Wards
The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
About this study
Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of pharmacogenetic testing as part of medication reviews reveals more serious drug related problems and leads to more changes in medication treatment than medication review alone.
The use of pharmacogenetic testing as part of medication reviews has not earlier been systematically investigated in hospital patients in Norway. There is little documentation of what is needed to implement the use of pharmacogenetic testing in a hospital ward.
The investigators are conducting a descriptive study in two internal medicine wards at Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least one relevant for pharmacogenetic testing will be enrolled in the study.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- at least 2 long-term conditions
- at least 5 regular drugs of which at least one relevant for pharmacogenetic testing
- at least 2 years life expectancy
- able to communicate in Norwegian
- able to give informed consent
- summary care record
Exclusion criteria
- moderate to severe dementia
Treatment and study plan
Pharmacogenetic test
Geneticgenotyping for genes that affect drug metabolism
Medication review
Othersystematic and interdisciplinary method aiming to increase quality of medication treatment
Primary outcomes
-
Number of patients with results from pharmacogenetic testing included in medication review
Time frame: from admission to discharge, an average of 1 week
Number of patients
Secondary outcomes
-
Acceptance of recommendations
Time frame: after medication review and before discharge, an average of 3 days
Degree of acceptance of recommendations after pharmacogenetic testing, by prescribers
-
Documentation of information from pharmacogenetic testing
Time frame: after medication review and before discharge, an average of 3 days
Number of patients with information from pharmacogenetic testing documented in the patient journal
Sponsors and collaborators
Lead sponsor
Hospital Pharmacy Enterprise, South Eastern Norway
Other
Collaborators
- Diakonhjemmet Hospital
- University Hospital, Akershus
- University of Oslo School of Pharmacy
Registry information
Official study title
Implementation of Pharmacogenetic Testing as Part of Medication Reviews in Hospital Wards
Acronym: FAGLIS
Important dates
- Study start
- 2020
- Primary completion
- 2021
- Study completion
- 2021
- First posted
- Oct 5, 2020
- Registry last updated
- Mar 9, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.